Posts

Posted on

Alto Ingredients, Inc. Directors to Not Stand for Reelection

PEKIN, Ill., March 18, 2025 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, today announced that two long-standing directors, Douglas L. Kieta and Michael D. Kandris, have decided they will not stand for reelection to the Alto Ingredients Board of Directors at the company’s 2025 Annual Meeting of Stockholders, scheduled for June 25, 2025.

Bryon McGregor, President and Chief Executive Officer of Alto Ingredients said “Doug and Mike have been exceptional board members, and they have provided excellent service to the company and our stockholders. Doug’s depth and breadth of experience, intellectual curiosity, technical acumen, and unwavering determination has been pivotal to the many improvements and successes at Alto. Mike’s dedication to excellence as a board member, his sound leadership as Chief Operating Officer and CEO, and personal approach will leave an enduring positive impact on Alto’s culture and employees. On behalf of everyone at Alto Ingredients, I want to extend a heartfelt thanks to Doug and Mike for their remarkable years of service.”

About Alto Ingredients, Inc.

Alto Ingredients, Inc. (NASDAQ: ALTO) is a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients. Leveraging the unique qualities of its facilities, the company serves customers in a wide range of consumer and commercial products in the Health, Home & Beauty; Food & Beverage; Industry & Agriculture; Essential Ingredients; and Renewable Fuels markets. For more information, please visit www.altoingredients.com.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995


Statements and information contained in this communication that refer to or include Alto Ingredients’ estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Alto Ingredients’ current perspective of existing trends and information as of the date of the communication. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning Alto Ingredients’ projected outlook and future performance, including the timing and effects of its cost savings initiatives and its acquisition of a liquid carbon dioxide processor adjacent to its Columbia plant; Alto Ingredients’ capital projects, including its carbon capture and storage (CCS) project and opportunities to optimize carbon; and Alto Ingredients’ other plans, objectives, expectations and intentions. It is important to note that Alto Ingredients’ plans, objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Alto Ingredients’ current expectations depending upon a number of factors affecting Alto Ingredients’ business and plans. These factors include, among others adverse economic and market conditions, including for renewable fuels, specialty alcohols and essential ingredients; export conditions and international demand for the company’s products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; adverse impacts of inflation and supply chain constraints; and the cost, ability to fund, timing and effects of, including the financial and other results deriving from, Alto Ingredients’ repair and maintenance programs, plant improvements and other capital projects, including CCS, and other business initiatives and strategies. These factors also include, among others, the inherent uncertainty associated with financial and other projections and large-scale capital projects, including CCS; the anticipated size of the markets and continued demand for Alto Ingredients’ products; the impact of competitive products and pricing; the risks and uncertainties normally incident to the alcohol production, marketing and distribution industries; changes in generally accepted accounting principles; successful compliance with governmental regulations applicable to Alto Ingredients’ facilities, products and/or businesses; changes in laws, regulations and governmental policies, including with respect to the Inflation Reduction Act’s tax and other benefits Alto Ingredients expects to derive from CCS; the loss of key senior management or staff; and other events, factors and risks previously and from time to time disclosed in Alto Ingredients’ filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Alto Ingredients’ Quarterly Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2025.

Company IR and Media Contact:

Michael Kramer, Alto Ingredients, Inc., 916-403-2755
[email protected]

IR Agency Contact:

Kirsten Chapman, Alliance Advisors Investor Relations, 415-433-3777
[email protected]



Posted on

Ingram Micro’s Xvantage Integrations Hub Delivers a Plug-and-Play Experience, Virtually Eliminating the Complexity of Software Integrations

Ingram Micro’s Xvantage Integrations Hub Delivers a Plug-and-Play Experience, Virtually Eliminating the Complexity of Software Integrations

Using AI to simplify integrating SaaS tools and platform technology into Xvantage, Ingram Micro is driving faster decision-making and revenues, while enabling more secure modern workflows

IRVINE, Calif.–(BUSINESS WIRE)–
Ingram Micro (NYSE: INGM), a business-to-business (B2B) platform company for the global technology ecosystem, is simplifying the technology industry’s capabilities to innovate and more securely integrate at scale faster with the global launch of its AI-powered Xvantage Integrations Hub.

Readily available in nine countries where Xvantage is deployed, Ingram Micro’s Xvantage Integrations Huboffers customers and vendors a frictionless experience, dramatically simplifying software integrations by enabling instant access to prebuilt applications and more secure modern workflows.

With the new Xvantage Integrations Hub, integrations that could have taken months can now be completed in seconds or minutes, helping customers and vendors significantly speed their transformations. Hub-spot, Salesforce, ZOHO and more are among the ready-to-deploy global and regional integrations. Dozens of additional integrations are expected to go live in the Xvantage Integrations Hub throughout 2025.

“The global platform and sharing economy are accelerating business transformation across industries, including the tech sector, and introducing a new wave of collaboration and resilience,” said Frank Della Rosa, Research Vice President, SaaS, Business Platforms, and Industry Cloud, IDC. “Ingram Micro’s Xvantage platform and new Xvantage Integrations Hub demonstrate the balance required between integrations and interactions to build a digitally-enabled organization that prioritizes the customer experience and business execution.”

Engineered in-house by Ingram Micro’s global platform group, the new Xvantage Integrations Hub uses the power of AI models to integrate instantly and securely with existing SaaS Platforms—including CRM, ERP, RMM, and CPQ (Configure, Price, Quote). This effort speeds up time to value and helps eliminate the need for costly custom software development. The Xvantage Integrations Hub also helps reduce manual workloads, empowering partners to scale efficiently and apply their talent to more valuable business and service lines.

“The Integrations Hub is modern, intuitive, and incredibly easy to navigate,” said Brayton Taylor, Owner, Taylor Tech LLC. “We were amazed at how quickly we installed an app—what normally takes months, we completed in minutes. The seamless experience and effortless setup make this a game-changer for integrations.”

“Integrations are critical in a platform economy—operating at the crux of a connected ecosystem that thrives on collective innovation and continuous transformation,” said Sanjib Sahoo, President of Global Platform Group, Ingram Micro. “At Ingram Micro, we are constantly driving technology innovations to help our partners. The focused, extensive groundwork we have laid in AI over the last few years has enabled this unique, industry-first solution, which is solving a real pain point for our customers and vendors and helping to drive their growth and success.”

“Platform integrations are the connective tissue of the AI-enabled future of the technology ecosystem,” said Ambrish Verma, Chief Product Officer, Ingram Micro. “With the Xvantage Integrations Hub, we are moving towards a platform-driven experience led by an AI-enabled team focused on achieving greater collaboration, productivity, and efficiency.”

Click here to view the U.S. Xvantage Integrations Hub.

About Ingram Micro

Ingram Micro is a leading technology company in the global information technology ecosystem. With the ability to reach nearly 90% of the global population, we play a vital role in the worldwide IT sales channel, bringing products and services from technology manufacturers and cloud providers to a highly diversified base of business-to-business technology experts. Through Ingram Micro Xvantage™, our AI-powered digital platform, we offer what we believe to be the industry’s first comprehensive business-to-consumer-like experience, integrating hardware and cloud subscriptions, personalized recommendations, instant pricing, order tracking, and billing automation. We also provide a broad range of technology services, including financing, specialized marketing, lifecycle management, and technical pre- and post-sales professional support. Learn more at www.ingrammicro.com.

Press Contact:

Marie Meoli Rourke

714-292-2199

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Apps/Applications Technology Software Artificial Intelligence Hardware

MEDIA:

Logo
Logo
Posted on

Intellicheck To Present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference

Intellicheck To Present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference

MELVILLE, N.Y.–(BUSINESS WIRE)–Intellicheck, Inc. (Nasdaq: IDN), an industry-leading identity company delivering proprietary on-demand digital and physical identity validation solutions, today announced that CEO Bryan Lewis will present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference taking place on March 25-26, 2025. Joining him at the conference will be CFO Adam Sragovicz.

The presentation will begin at 2:00 p.m. ET on Tuesday, March 25. A webcast of the presentation will be available at https://www.webcaster4.com/Webcast/Page/3083/52207

Intellicheck CEO Lewis and CFO Sragovicz will also host virtual one-on-one meetings with investors on March 26, 2025. For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Intellicheck, please visit the conference website at https://www.iaccessalpha.com/home.

About Intellicheck

Intellicheck is the leader in fraud identity management, delivering on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. Our solution enables you to bring revenue generating capabilities online faster, so you can achieve greater productivity gains and accelerate customer acquisition. With more than two decades of experience, our mission is to provide seamless, invisible customer experiences with 100% decisioning in under a second. Each year, we validate more than 100 million identities across North America. For more information on Intellicheck, visit us on the web and follow us on LinkedIn, X, Facebook, and YouTube.

Investor Relations: Gar Jackson (949) 873-2789 / [email protected]

Media and Public Relations:Sharon Schultz (302) 539-3747 / [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Software Hardware Banking Accounting Professional Services Technology Mobile/Wireless Security

MEDIA:

Logo
Logo
Posted on

Strategy Announces Proposed STRF Perpetual Preferred Stock Offering

Strategy Announces Proposed STRF Perpetual Preferred Stock Offering

TYSONS CORNER, Va.–(BUSINESS WIRE)–
Strategy™ (Nasdaq: MSTR; STRK) today announced that, subject to market and other conditions, it intends to offer, in a public offering registered under the Securities Act of 1933, as amended (the “Securities Act”), 5,000,000 shares of Strategy’s Series A Perpetual Strife Preferred Stock (the “perpetual strife preferred stock”).

Strategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of bitcoin and for working capital.

The perpetual strife preferred stock will accumulate cumulative dividends at a fixed rate of 10.00% per annum on the stated amount. Regular dividends on the perpetual strife preferred stock will be payable when, as and if declared by Strategy’s board of directors, out of funds legally available for their payment, quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on June 30, 2025. Declared regular dividends on the perpetual strife preferred stock will be payable solely in cash. In the event that any accumulated regular dividend on the perpetual strife preferred stock is not paid on the applicable regular dividend payment date, then additional regular dividends (“compounded dividends”) will accumulate on the amount of such unpaid regular dividend, compounded quarterly. The compounded dividend rate applicable to any unpaid regular dividend that was due on a regular dividend payment date will initially be a rate per annum equal to 10% plus 100 basis points; provided, however, that, until such regular dividend, together with compounded dividends thereon, is paid in full, such compounded dividend rate will increase by 100 basis points per annum for each subsequent regular dividend period, up to a maximum dividend rate of 18% per annum.

Strategy will have the right, at its election, to redeem all, but not less than all, of the perpetual strife preferred stock, at any time, for cash if the total number of shares of perpetual strife preferred stock then outstanding is less than 25% of the total number of shares of the perpetual strife preferred stock originally issued in the offering and any future offerings, taken together. In addition, Strategy will have the right to redeem all, but not less than all, of the perpetual strife preferred stock if certain tax events occur. The redemption price for any perpetual strife preferred stock to be redeemed will be a cash amount equal to the liquidation preference of the perpetual strife preferred stock to be redeemed as of the business day before the date on which Strategy sends the related redemption notice, plus accumulated and unpaid regular dividends to, but excluding, the redemption date.

If an event that constitutes a “fundamental change” under the certificate of designations governing the perpetual strife preferred stock occurs, then holders of the perpetual strife preferred stock will have the right to require Strategy to repurchase some or all of their shares of perpetual strife preferred stock at a cash repurchase price equal to the stated amount of the perpetual strife preferred stock to be repurchased, plus accumulated and unpaid regular dividends, if any, to, but excluding the fundamental change repurchase date.

The liquidation preference of the perpetual strife preferred stock shall initially be $100 per share (the “stated amount”). Effective immediately after the close of business on each business day after the initial issue date (and, if applicable, during the course of a business day on which any sale transaction to be settled by the issuance of perpetual strife preferred stock is executed, from the exact time of first such sale transaction during such business day until the close of business of such business day), the liquidation preference per share will be adjusted to be the greatest of (i) the stated amount; (ii) in the case of any business day with respect to which we have, on such business day or any business day during the ten trading day period preceding such business day, executed any sale transaction to be settled by the issuance of perpetual strife preferred stock, an amount equal to the last reported sale price per share of perpetual strife preferred stock on the trading day immediately before such business day; and (iii) the arithmetic average of the last reported sale prices per share of perpetual strife preferred stock for each trading day of the ten consecutive trading days (or, if applicable, the lesser number of trading days as have elapsed during the period from, and including, the initial issue date to, but excluding, such business day) immediately preceding such business day.

Morgan Stanley & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc. and Moelis & Company LLCare acting as joint book-running managers for the offering.

The offering is being made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and an accompanying prospectus. An electronic copy of the preliminary prospectus supplement, together with the accompanying prospectus, is available on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement, together with the accompanying prospectus, can be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by phone: 1-866-718-1649 or by email: [email protected], or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone 1-888-603-5847, or by email: [email protected], or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146, or by email: [email protected], or Moelis & Company LLC, 399 Park Avenue 4th Floor, New York, NY 10022, by phone: 1-800-539-9413.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to in this press release, nor will there be any sale of any such securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Strategy

MicroStrategy Incorporated d/b/a Strategy (Nasdaq: MSTR/STRK) is the world’s first and largest Bitcoin Treasury Company. We are a publicly traded company that has adopted Bitcoin as our primary treasury reserve asset. By using proceeds from equity and debt financings, as well as cash flows from our operations, we strategically accumulate Bitcoin and advocate for its role as digital capital. Our treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. In addition, we provide industry-leading AI-powered enterprise analytics software, advancing our vision of Intelligence Everywhere. We leverage our development capabilities to explore innovation in Bitcoin applications, integrating analytics expertise with our commitment to digital asset growth. We believe our combination of operational excellence, strategic Bitcoin reserve, and focus on technological innovation positions us as a leader in both the digital asset and enterprise analytics sectors, offering a unique opportunity for long-term value creation.

Strategy, MicroStrategy, and Intelligence Everywhere are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the size and timing of the offering, the anticipated use of any proceeds from the offering and the terms of the securities being offered. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all, the other factors discussed in the “Risk Factors” section of Strategy’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 18, 2025 and the risks described in other filings that Strategy may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Strategy specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Strategy

Shirish Jajodia

Corporate Treasurer

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Technology Finance Professional Services Digital Cash Management/Digital Assets Software Data Analytics Cryptocurrency Asset Management Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models

  • Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours.
  • Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays.
  • Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft model, HT-KIT treatment (12.5 mg/kg IV every three days) led to a significant reduction in tumor growth, with differences becoming statistically significant by day 8 and increasing over time.
  • Consistent Tumor Size Reduction – Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements.


NEW YORK
, March 18, 2025 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). The results highlight HT-KIT’s ability to significantly reduce tumor burden in humanized mouse models, disrupt KIT signaling pathways, and induce tumor cell death.

“These exciting findings mark a significant milestone in the development of HT-KIT as a potential new therapeutic for patients with GIST,” said Robb Knie, CEO of Hoth Therapeutics.

“By targeting KIT mutations, which are a major driver of GIST progression, HT-KIT has shown remarkable efficacy in preclinical models, demonstrating its potential as a transformative treatment option for this difficult-to-treat cancer.”

Key Findings from the Preclinical Study:

  • Significant Reduction in KIT Expression – HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours.
  • Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours.
  • Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays.
  • Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft model, HT-KIT treatment led to a significant reduction in tumor growth, with differences becoming statistically significant by day 8 and increasing over time.
  • Consistent Tumor Size Reduction – Excised tumors from HT-KIT-treated mice were smaller and lighter than those in the control group, reinforcing tumor volume measurements.

HT-KIT: A Potential New Treatment for GIST

GIST is a rare but aggressive cancer often driven by activating mutations in the KIT receptor. Current treatment options, including tyrosine kinase inhibitors (TKIs), can face resistance over time, leading to disease progression. Hoth Therapeutics’ HT-KIT offers a novel approach by effectively reducing KIT receptor expression, disrupting tumor survival pathways, and inhibiting tumor growth in vivo.

“These results provide compelling preclinical proof-of-concept for HT-KIT in GIST treatment,” said Robb Knie. “By directly targeting the underlying genetic drivers of GIST, HT-KIT has the potential to overcome limitations of existing therapies and provide a new therapeutic strategy for patients with KIT-driven malignancies.”

Next Steps in Development

Hoth Therapeutics is committed to advancing HT-KIT toward clinical evaluation. The company is currently conducting additional preclinical studies to further validate HT-KIT’s efficacy and safety profile, with plans to initiate regulatory discussions for first-in-human trials.

For more information on Hoth Therapeutics and its innovative pipeline, please visit www.hoththerapeutics.com.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth’s current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC 
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-preclinical-results-for-ht-kit-in-aggressive-cancer-gastrointestinal-stromal-tumors-gist-ht-kit-triggered-significant-tumor-cell-death-as-early-as-24-hours-post-treatment-302403945.html

SOURCE Hoth Therapeutics, Inc.

Posted on

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.

William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “Tackling the Tough Questions in IO for Autoimmunity Disease.” After, he will Chair the session, “State of the IO Market, Investments and Deals Plenary.”

During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of “Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager,” and provide a corporate overview of IN8bio’s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.

As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.

Presentation and Panel Details

Co-Chairs’ Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease

  • Date/Time: March 25, 2025, at 8:15 AM EDT

Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager

  • Date/Time: March 25, 2025, at 4:35 PM EDT

For those interested in coordinating a time to meet with the IN8bio during IO360°, please email [email protected].

For more information about the event, visit https://io360summit.com.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:

Glenn Schulman, PharmD, MPH
203.494.7411
[email protected]

IN8bio, Inc.
Patrick McCall
646.933.5603
[email protected]

Media Contact:

Kimberly Ha
KKH Advisors
917.291.5744
[email protected]



Posted on

Foresight Announces the Integration of NVIDIA Jetson Orin into its 3D Perception Systems

Foresight to equip autonomous drones and unmanned aerial vehicles with NVIDIA Jetson Orin platform for enhanced real-time perception, obstacle detection, and energy efficiency across diverse applications

NESS ZIONA, Israel, March 18, 2025 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), a leading innovator in 3D perception systems, announces the integration of NVIDIA Jetson Orin computing platforms into its cutting-edge perception technologies.

The collaboration, previously announced on February 24, 2025, leverages NVIDIA Jetson Orin Nano and NVIDIA Jetson AGX Orin platforms to enhance the capabilities of Foresight’s 3D perception systems across various industries, with focus on autonomous drones and unmanned aerial vehicles (UAV).

The NVIDIA Jetson Orin platform provides Foresight’s vision systems with state-of-the-art computing power tailored to the unique requirements of autonomous drones and UAVs. The NVIDIA Jetson Orin Nano is optimized for compact, lightweight drones and UAVs, offering robust artificial intelligence (AI) performance and energy efficiency while minimizing weight and size. These platforms reduce power consumption while maintaining high performance, making them ideal for drones in large-scale or remote-area applications. For higher-performance needs, the NVIDIA Jetson AGX Orin delivers up to 275 trillion operations per second (TOPS), enabling real-time data processing, advanced obstacle detection, and precise terrain mapping in complex and dynamic environments.

By leveraging the advanced AI and graphics processing unit (GPU) capabilities of NVIDIA Jetson platforms, Foresight continues to revolutionize the field of autonomous drones and UAVs, delivering 3D perception solutions that set new benchmarks for performance, efficiency, and adaptability.

Foresight’s 3D perception systems, using both visible light and thermal long-wave infrared cameras, enable comprehensive environmental perception across diverse and challenging conditions, including low-light environments, heavy fog, and extreme weather scenarios. The technology offers unparalleled capabilities for applications that demand reliable and precise environmental understanding such as search and rescue missions and agriculture monitoring.


About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the Company’s wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (3D) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the benefits and advantages of NVIDIA Jetson Orin platforms, the benefits and advantages of Foresight’s products and technology, particularly with the integration of the NVIDIA Jetson Orin platforms and that this collaboration has significant potential for autonomous drone and UAVs. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 27, 2024, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the contents of third-party websites. 

Investor Relations Contact:

Miri Segal-Scharia
CEO
MS-IR LLC
[email protected]
917-607-8654



Posted on

StepStone Group Announces 2025 Partner and Managing Director Promotions

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, has named 10 new partners and 24 new managing directors.

Partner and CEO Scott Hart said, “The momentum of the StepStone franchise is as strong as ever, which is a testament to the great talent we have attracted, cultivated, and promoted into leadership positions over the years. Congratulations to the newest class of partners and managing directors.”

2025 Partner Class

  • Christopher Bernadino joined StepStone in 2015 and is based in La Jolla. He serves as Global Head of Information Technology and Chief Information Security Officer.
  • Elizabeth Ferry joined StepStone in 2019 and is based in La Jolla. She serves as Head of Operational Due Diligence.
  • Anthony Giambrone joined StepStone in 2021 and is based in Baltimore. He is a member of the Venture Capital and Growth Equity team.
  • Remo Kämpf joined StepStone in 2016 and is based in Zurich. He is a member of the Private Debt team.
  • Laia Massague joined StepStone in 2017 and is based in London. She is a member of the Real Estate team.
  • Pooja Patel joined StepStone in 2014 and is based in London. She is a member of the Real Estate team.
  • Tim Rees joined StepStone in 2014 and is based in London. He is a member of the Infrastructure and Real Assets team.
  • Anja Ritchie joined StepStone in 2020 and is based in Frankfurt. She is a member of the Real Estate team.
  • Stephen West joined StepStone in 2021 and is based in Baltimore. He is a member of the Venture Capital and Growth Equity team.
  • Joey Wong Castillo joined StepStone in 2020 and is based in London. She serves as Head of Legal, Infrastructure and Real Assets.

New Managing Directors

  • Michael Bermel, Private Wealth, Charlotte
  • Elise Chanlatte, Fund Accounting, La Jolla
  • Jo-Anne Curchod, Corporate Finance and Accounting, Zurich
  • James Connolly, Operations, Dublin
  • Alec Darbyshire, Real Estate, San Francisco
  • Colin Donnelly, Real Estate, Chicago
  • Sean Doyle, Private Debt, Dublin
  • JD Hall, Venture Capital and Growth Equity, Baltimore
  • Patrick Hart, Product Management, La Jolla
  • Nichole Kim, Private Equity, New York
  • Daniel Krikorian, Private Equity, La Jolla
  • Gray Layden, Real Estate, San Francisco
  • Richard Lowe, Real Estate, London
  • Alex Morsy, Data and Software Engineering, La Jolla
  • Akhilan Nesaratnam, Private Equity, London
  • Simi Olusoga, Product Management, New York
  • Miriam Penney, Operational Due Diligence, Dublin
  • Selin Pinarci, Product Management, Zurich
  • Dylan Quesada, Product Management, New York
  • Veith Riebow, Business Development, Frankfurt
  • Jared Root, Private Debt, New York
  • Nicholas Russell, Portfolio Analytics and Reporting, La Jolla
  • Jonathan True, Private Equity, New York
  • Theodore Wong, Product Management, New York

About StepStone

StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of December 31, 2024, StepStone was responsible for approximately $698 billion of total capital, including $179 billion of assets under management. StepStone’s clients include some of the world’s largest public and private defined benefit and defined contribution pension funds, sovereign wealth funds and insurance companies, as well as prominent endowments, foundations, family offices and private wealth clients, which include high-net-worth and mass affluent individuals. StepStone partners with its clients to develop and build private markets portfolios designed to meet their specific objectives across the private equity, infrastructure, private debt and real estate asset classes.

Contacts

Shareholder Relations:

Seth Weiss
[email protected]
+1 (212) 351-6106

Media:

Brian Ruby / Chris Gillick / Matt Lettiero, ICR
[email protected]
+1 (203) 682-8268



Posted on

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) — – 
SCIENTURE HOLDINGS, INC.
NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand name ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL. ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.

ArbliTM is a novel proprietary formulation of losartan, a proven therapy for treating hypertension, which provides a tailored approach to patients that require or prefer an oral liquid option of losartan. Appropriate dosing is now easier, safe and effective, while providing the assurance of quality as an FDA-approved product. ArbliTM provides a safe and convenient option to patients requiring a liquid formulation and addresses the intrinsic risks associated with potential inconsistencies in the process of crushing tablets to extemporaneously compound losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also expected to be listed in the FDA Orangebook.

Losartan is classified as an angiotensin receptor blocker (ARB) for treating hypertension and is one of the highest prescribed molecules for this indication. Current products in the market containing losartan are available only as oral solids, which can be further compounded to a liquid formulation. ArbliTM is the first liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market.

“The approval of ArbliTM exemplifies our deep commitment to develop high value products that address unique and underserved patient needs. A significant number of patients can benefit from a safe and efficacious ready-to-use oral liquid formulation of losartan. We are excited with the approval of our first brand product which is part of our upcoming pipeline of novel specialty products,” remarked Shankar Hariharan, CEO of Scienture, LLC.

“We are pleased to bring to market, ArbliTM, a transformative therapy option containing losartan, one of the most widely prescribed molecules in its class, to patients, caregivers and healthcare professionals (HCPs). We expect to commercially launch and make ArbliTM available to patients in the U.S. in Q3 2025,” said Narasimhan Mani, President of Scienture, LLC.

“This announcement is extremely exciting and is a clear demonstration of the value Scienture, LLC brings to the combined company and its shareholders,” said Suren Ajjarapu, Chairman of the Board, Scienture Holdings, Inc.

About Arbli

TM

ArbliTM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 18 months from the date of manufacture when stored at room temperature, based on the data submitted in the NDA. Once the 24-months stability data is submitted to the FDA, the shelf-life of the product is expected to be extended to 24-months at room temperature.

INDICATION

ArbliTM is an angiotensin II receptor blocker (ARB) indicated for:

  • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
  • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. 

IMPORTANT SAFETY INFORMATION

  • Do not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible.
    Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
  • Do not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in patients with renal impairment (GFR <60 mL/min).
  • Do not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients with severe hepatic impairment.
  • The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider. 

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg. 

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. 

Contact:

SCIENTURE HOLDINGS, INC.

6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: [email protected]



Posted on

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

PR Newswire

  • The company is expected to reduce core operational burn by 55% when compared to 2024


EDINBURGH, Scotland
, March 18, 2025 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company’s strategic developmental plan. 

The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and other cell therapy production technologies. Additionally, the company is reviewing alternative approaches for testing and clinical needs, which align with a decentralized drug development model.  This approach is expected to result in a workforce reduction of approximately 20 employees, focused largely within the company’s production and quality divisions and represents approximately half of the company’s total headcount. Separations will be substantially complete by the end of the second quarter 2025 and are expected to reduce the core operational burn rate by approximately 55% compared to 2024.  As a result of these steps, when compared to 2024, the Company estimates partial year 2025 savings to be approximately $2.1 million and annualized savings to be roughly $4.2 million.  

“This decision to reduce staff is attributable to the company’s strategic shift in focus towards an outsourced production model and something that we believe will ultimately better position TC BioPharm for future clinical trial plans as well as advancements in new cell therapy manufacturing technologies,” said Bryan Kobel, CEO of TC BioPharm. “We are at a pivotal moment in our development as we expand into new indication verticals, prepare for ACHIEVE data review which will drive our next clinical pathway, and reduce the need for costly in-house expenses to provide a stronger foundation for future growth. I arrived at this decision knowing it will be difficult to say goodbye to colleagues who have been a significant part of TC BioPharm’s culture and accomplishments. I’m grateful to all those who have shared in our history and to those who will continue to usher in the next phase of TCBP.”  

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

Forward-Looking Statements for TC BioPharm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management’s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-outsourcing-initiatives-reducing-burn-rate-and-overhead-302403910.html

SOURCE TC BioPharm